We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
ImmunityBio, Inc.
Health Care · Biotechnology
Structural: Only IL-15 superagonist with an FDA approval in oncology. Anktiva's NMIBC label addresses ~10k US patients/year where the alternative is radical cystectomy; commercial ramp began mid-2024 with payer access widening through 2025.
Pipeline reads (lung w/ checkpoint, pancreatic, HIV) extend the same molecule across high-unmet-need indications without new platform risk.
- Anktiva sales inflecting from launch base; gross-to-net stabilizing as Medicare/commercial coverage broadens
- Label-expansion catalysts in NSCLC (post-checkpoint failure) and lymphopenia readouts through 2026
- Soon-Shiong has personally backstopped financings, reducing acute dilution-shock risk vs typical clinical biotech
- Manufacturing in-house (Dunkirk, NY + El Segundo) - rare for a biotech this size, supports gross margin scale
- Strategic optionality: NantKwest cell-therapy assets, BioShield vaccine platform sit inside the same corporate wrapper
- Operating cash burn still materially exceeds Anktiva revenue; another raise inside 12-18 months is the base case
- Patrick Soon-Shiong control (>60%) means minority shareholders are price-takers on dilutive financings
- Going-concern language has appeared in past 10-Qs; auditor risk is non-trivial
Each weekday: the scan's ENTER setups with entry, stop and target, every new ticker teardown, and the bubble shifts that move names like this one. Free. Education, not advice.
No spam. One email per day max. Pro adds Telegram trade alerts and higher AI-assistant limits.
- Float dynamics + retail concentration make $IBRX a high-beta, narrative-driven name vs cleaner biotechs like $VRTX or $REGN
No major news in the last 7 days for IBRX - only listicles and opinion pieces, which we filter out by default. See everything anyway.
Auto-computed retracement of the trailing 52w low-high leg. Recomputed on each refresh; not a curated level.
Auto-computed retracement of the trailing 52w low-high leg. Recomputed on each refresh; not a curated level.